Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

o fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dep
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 /PRNewswire-iReach/ -- Reproductive Medicine Associates of New ... ), a nationally and internationally-recognized leader in providing exceptional ... is pleased to announce a new collaboration with EMD ... to recognize the sacrifices made by veterans and their ... Program will allow qualifying veterans and the spouses of ...
(Date:7/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... chief financial officer of the company, effective July 22, ... president and chief financial officer of Elan Corporation, a ... was part of a senior team that helped build ... to Perrigo, a pharmaceutical manufacturer, in December 2013. ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) Inc. ... medical device R&D outsourcing company with operations in ... , today announced that it will release financial results for ... Exchange closes on Wednesday, August 13, 2014 (which will be ... will be available on the investor relations section of the ...
Breaking Medicine Technology:Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3ConvaTec Names Nigel Clerkin Chief Financial Officer 2WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
(Date:7/22/2014)... from Boston University School of Medicine (BUSM) and ... who received care through BMC,s Violence Intervention Advocacy ... emotional and social needs of violently injured youthswere ... experienced life changing behaviors through connections to caring, ... and hope. These findings are reported in the ...
(Date:7/22/2014)... from the Sloan-Kettering Institute for Cancer Research in New ... Schools of Medicine and Dentistry have completed research which ... how some cells in the brain and nervous system ... published in the prestigious journal Cancer Cell . ... a tumour suppressor called Merlin. , The results ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 BlogHer, ... for women, this year celebrates its tenth anniversary where ... Thousands of attendees, including community leaders from the new ... representing every consumer vertical, will converge in San Jose ... conversation, and a “selfiebration” of social technology. , ...
(Date:7/22/2014)... SWAMP , the first ... has completed an upgrade that significantly improves the ... with a $23.4 million grant from the ... (DHS S&T), the Software Assurance Marketplace (SWAMP) ... to assess the security of their software, but ...
(Date:7/22/2014)... New study findings released today confirm ... patient-centered program is working to improve the coordination of ... the largest to date and includes more than 200,000 ... that focuses on delivering better quality outcomes, a better ... , “Our most recent study results clearly demonstrate the ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Research brings us nearer to understanding how neuro cells turn cancerous 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 2Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 3Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 5Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 2Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 3
... Global health organization PSI helps contestants spread HIV prevention ... Bahamas, Aug. 21 The Miss Universe contestants continued preparations for ... tossing water-filled condoms to test their strength and playing "Wild Fire ... The games are part of an HIV peer education workshop designed ...
... ... Mesothelioma Patients , ... Newton, MA (PRWEB) August 21, 2009 -- MesoRC.com, an online community and resource center ... diseases, provides an extra source of valuable information with the introduction of Twitter. The ...
... , , LOS ANGELES, Aug. ... the launch of Energy-X, a new lip balm that delivers an effective ... sweeteners. With zero calories, Energy-X provides the energy boost consumers want without ... "Energy-X is applied directly on the lips and is therefore ...
... , , , ... to a Benefit Concert, Dessert and Auction, featuring LA Collaboration, at ... , 1243 Artesia Blvd, Manhattan Beach, CA - (310) 372-4641 ... price of 1 tickets. , , The concert features ...
... treating a recurrent or residual brain aneurysm that was ... a multicenter study led by researchers at the University ... of 311 patients with coiled aneurysms who underwent retreatment ... death or permanent major disability was slightly over one ...
... , FRAMINGHAM, Mass. and SYDNEY, Aug. ... announced that HeartWare has surpassed 50 implants in the United States ... , , The 50th implant in the ... Houston, Texas by O.H. Frazier, MD a distinguished surgeon, scientist, and ...
Cached Medicine News:Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Mesothelioma Resource Center Enters Twitter World 2Health News:Energy-X Lip Balm Delivers Wake-Up Call to Consumers 2Health News:The Sensory Research Center (SRC) Offers 2 for 1 Tickets for Benefit Concert Supporting Autism, Down's Syndrome, Cerebral Palsy and Other Disabilities. 2Health News:Study finds low risk in treating previously coiled aneurysm 2Health News:Study finds low risk in treating previously coiled aneurysm 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple intuitive ...
... modified battery chargers are ... for GENIE blotters. They ... very specific voltages, giving ... laboratory power supplies. 110 ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Inquire...
Medicine Products: